Share Name Share Symbol Market Type Share ISIN Share Description
BTG Plc LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.00p -1.49% 661.00p 661.00p 662.00p 674.50p 659.00p 671.00p 367,750 16:35:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 570.5 31.6 8.7 76.0 2,553.44

BTG (BTG) Latest News

More BTG News
BTG Takeover Rumours

BTG (BTG) Share Charts

1 Year BTG Chart

1 Year BTG Chart

1 Month BTG Chart

1 Month BTG Chart

Intraday BTG Chart

Intraday BTG Chart

BTG (BTG) Discussions and Chat

BTG Forums and Chat

Date Time Title Posts
12/11/201308:46BTG down the tube6
09/3/201207:16Bright Things3
10/9/200419:24Varisolve hits the FDA buffer's6

Add a New Thread

BTG (BTG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all BTG trades in real-time

BTG (BTG) Top Chat Posts

BTG Daily Update: BTG Plc is listed in the Support Services sector of the London Stock Exchange with ticker BTG. The last closing price for BTG was 671p.
BTG Plc has a 4 week average price of 659p and a 12 week average price of 659p.
The 1 year high share price is 784p while the 1 year low share price is currently 556p.
There are currently 386,299,436 shares in issue and the average daily traded volume is 317,694 shares. The market capitalisation of BTG Plc is £2,553,439,271.96.
ugandalad: As a long term holder who is doing very well from this speculative share there seems to be an over reaction to the Legal action decision which first came to light on 20th September 2017. 10 days before this the share price was at 705p on the 11 days preceding the announcement the price dropped to 665p on the day of the announcement. Since then it has climbed steadily with the implications of the judgement known to the market. The latest drop of around 6% puts the price back about 3 weeks. As this share does fluctuate between hard news there is nothing unusual. Given the changes in the company since I first invested I see the process as on going. The CEO is managing the process not the share price but if it rises to 786 I will have doubled my money ignoring the profits I have already banked. I think this team is quite visionary operating in a difficult industry so expect the odd b*lls up. IMHO
bargainbob: From Dave on eye eye eye Im SORRY but my last post should not have been posted, as it wasn’t finished, I must have hit the wrong button before leaving my computer this morning. ---- --------------------------------------------------------------------------------- Reading the judgement posted here on the BB it makes my blood boil ,to read BTG were first approached by wellstadt with their suspicions many years ago but instead of talking to wellstadt, our management decided to instigated a breach of contract law suit against wellstadt instead ,now had the management agreed back then to return to the terms of that agreement ,then none of this would have happened ,and we would still be selling a licenced product for profit. How mad is that ?. I know from my own experience ,the last thing you do is attack a customer ,or a company you are working with, unless your 100% confident they had done something wrong, and that you could prove in a court of law and after talking to the company, to see if you could iron out the difficulties amicably ,but it appears in this case, BTG didn't do that ,and that to me ,that is asking for trouble. What's even more concerning about this, is that control of the sales & marketing budgets were changed after the agreement was signed, and would be detrimental to the launch of wellstedt product, and would break the terms of our contract with wellstadt, yet nobody at BTG saw this as a problem . To me all of this could have been avoided, had the BOD listened to Wellstads grievances in 2015. Had they done that ,then we wouldn’t be losing a product that could have made BTG a very good profit over many years, and for what is said to have been a very little amount of outlay according to the trial notes, and that to me is unforgivable, how this will play out with other clients, or with future clients ,I just don’t know, but as we all know 50% of business is about trust ,and if you lose that in the USA , then you are finished as most medical products in the U.S.A are purchased through a medical insurance syndicate . This whole sorry business shows how bad our marketing has been over the years, it could also explain why other BTG products we have launched in the USA, have also failed to meet expectations, or their growth predictions over the years ,and is something I, and many other posters on this BB have queried on several occasions , well maybe now we have the answer to all those questions ,as It seems to me, BTG either have a poor sales &marketing dept ,or B.T.G, lack the experience in the top echelons of the company, when it comes to sales &marketing . I know from my own experience in manufacturing and retail that most companies in UK today employ professional sales and marketing people ,as they know how to support a team of sales people and also know how to distribute a sales team across an area in order to maximise sales, they are also aware of the importance of marketing when launching a new product ,it’s their expertise of the market that is key to the success or failure of a product ,so if ,but if our management team can’t do that with in a set budget then heads should roll, I also believe ,that any shares received by the BOD through the BTG share initiative, should now be returned/or the cash repaid to the company, as they obviously failed in their responsibilities to the protect B.T.G shareholders profits, and the good name of the company ,But had the BOD acted upon wellstadt complaint back in 2015 things might be different now . Obviously we will never know the full story of what happened, or who was to blame for this mess ,but this sorry tale could have been soughed out amicably in 2015, and hopefully it still can be, as the judge has given both parties 21 days to find a settlement before ordering costs and payment . BE HAPPY DAVE ..
aphrodites: Having suffered a DVT myself a couple of years ago in my right leg and with a vein from my knee to my groin now blocked for life, I am probably more aware than most about the advantages the treatment with the EKOS system will provide to the medical world. The present treatment to unblock veins is very primitive and the success rate very, very low indeed. The damage caused to the valves in veins is irreparable unless the blockage is cleared very quickly. The market for the treatment of DVTs is massive and contrary to general opinion the condition is not restricted just to the elderly. I am reliably informed by an air hostess that a young lady of 34 y.o.a suffered a DVT on a flight and actually died on the plane. DVT's are very common indeed. I did have the statistics somewhere but cannot put my hands on them. Maybe someone else can provide. The announcement today has in my opinion far greater implications to the BTG share price than is fully appreciated and I am surprised the price is not back over £7 and moving higher. But it is a Friday. Obviously we will have to wait for the analysts to digest the news and get the blue pencils out next week. Have a good weekend everyone. Onwards and upwards.
muffmitz: The prats who are running AQR Capital Management still have a significant short position in BTG. Indeed they increased that position just over two weeks ago. In the meantime they have unleashed a torrent of bots in their attempts to manipulate the share price for their purposes. That is why there have been recently even more frequent and irrational fluctuations in the share price I think it's laughable to ascribe these movements to rational forces like the prospects for Varithena, the company's results, the high PE ratio etc etc. These have hardly changed during the recent greater turbulence. BTG is currently in the top 100 shorted shares in the UK market. All these forays must eventually come to an end, more than likely to the benefit of holders of BTG. Meanwhile it's the algorithms, stupid!
aphrodites: fhmktg You should breath in again and wait for news possibly on the 15th which could be very important for the share price. And as for Crofab why not update everyone with the news released today, not massive but nevertheless interesting and was not the reason for today's price rise??????????? New Study Shows Patients Treated With CroFab® Have Improved Recovery From Copperhead Envenomation PHILADELPHIA, June 13, 2017 /PRNewswire/ -- A study sponsored by BTG plc (LSE: BTG), the global specialist healthcare company, has been recently published in the Annals of Emergency Medicine (AEM) that shows administering CroFab® to patients envenomated by copperhead snakes can aid the recovery of a patient's affected limb function as compared with placebo. (Logo: hxxp:// ) The randomised, double-blind, placebo-controlled study compared CroFab® Crotalidae Polyvalent Immune Fab (Ovine) - the only antivenom currently marketed for the treatment of crotaline snake envenomation - against placebo for the treatment of copperhead snake envenomation for the first time. Copperhead envenomation is generally considered less severe than other North American Pit Viper snakebites, but more than 95% of copperhead victims still develop significant pain and swelling of the injured limb, and other soft tissue injury. Most patients resume activities within 2-4 weeks but residual symptoms can last for a year. Dr Charles Gerardo, Chief of Emergency Medicine at Duke University and expert in Copperhead snake envenomation, said: "For the first time, this data demonstrates that CroFab® improves recovery of limb function from Copperhead envenomation. Additionally, antivenom treatment was associated with less opioids use throughout the patient's recovery. These results can be used to help physicians and patients make a more informed choice about their care." In total, 74 patients participated in the study; 45 were treated with CroFab® and the rest received a placebo. All participating trial staff (apart from the study pharmacist) and patients were unaware of the treatment given in each case. Within the patient cohort was a mix of upper and lower extremity conditions depending on where the copperhead had bitten the patient. The Patient Specific Functional Scale (PSFS) was used to measure study outcomes by assessing each patient's ability to do daily activities that they were unable to do or had difficulty with post copperhead inflicted injury. The tasks varied from driving a car, climbing the stairs, brushing teeth, or using a cell phone and took in to account the score at envenomation + 14 days using a 0-10 scale. In addition to the positive primary outcome of the study, it was also discovered that opioid analgesic use was less in CroFab® treated patients. Dan Schneider, SVP and General Manager, Specialty Pharmaceuticals, Commercial Operations at BTG, said: "We are pleased with the clinical study findings that show that patients treated with CroFab® recover faster from Copperhead bites. Even though we haven't reached summer months yet, we are seeing multiple reports stating that the frequency of bites in the U.S. are on the rise this year. As snake sightings start to pick up, don't forget to download our free, educational SnakeBite911™ App Suite. It has useful information about the dos and don'ts if envenomation occurs and helps raise awareness about North American Pit Vipers." To review the published article in full, please refer to the following link: hxxp:// Indication CroFab® Crotalidae Polyvalent Immune Fab (Ovine) is a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins. Important Safety Information The most common adverse reactions reported in the clinical studies were urticaria, rash and nausea. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Anaphylaxis and hypersensitivity reactions can occur, and patients should be monitored closely during treatment. CroFab® should not be administered to patients with a known history of hypersensitivity to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available. In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required rehospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug. About BTG BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: For further information contact: BTG Andy Burrows, VP Corporate & Investor Relations
aphrodites: bargainbob BTG is not about always delivering blockbuster products. It is a relatively “young” company and as it states it is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. Its portfolio today already highlights its specialisation in Interventional Medicine and as it success grows so will its reputation to attract and help develop many more new blockbusting products to take to the market. Of course there will be disappointments along the way but that is always a feature and factor you have to build into the line of business it is in. I mentioned £20 as a target price for the future. That is not my expectation for tomorrow. But with a company like this, successful new innovations can deliver surprises in a share price that one never anticipated. As you are probably aware, BTG is a favourite of Fund Manager Neil Woodford. Last year he was reported as saying: “BTG currently resides in the FTSE 250 but my guess is that growing cash generation will end up propelling the fast-growing enterprise into the top index one day. In a recent update, BTG revealed double-digit revenue growth as it continues to make progress with several products.” Right now, BTG doesn’t pay a dividend but the firm’s strong cash flow suggests plenty of potential to do so down the road. In the meantime, investors will likely enjoy share-price growth as long as the company keeps gaining market share. City analysts following BTG predict an uplift of around 37% in earnings per share for the year to March 2018, so growth potential is on the table. Meanwhile, Imperial Brands thinks its earnings will inflate by 12% during the year to September 2017. That’s a good enough reason for me to hold this share in my portfolio and if it does continue to gain market share, the expectation of £20 down the road becomes more than a reality.
cyman: well the last sell recommendation to 565 (I think it was) proved to be a huge success and we were all laughing at it when we were basking in the sunshine of 800p. btg share price reactions of the past have often proven themselves to have been huge over-reactions - like when Louise settled her divorce, everyone was accusing her of all manner of sorcery - so hopefully this too was nothing more than an over reaction and we can start to settle back into the 600's whilst we await next years forecasts etc.
spyder: Here are my thoughts on what is happening with the BTG share price, for what they are worth. I suggested in posts to this board several times in the last few months, and most recently at around the time of the results, that the BTG share price was approaching very dangerous chart territory. If it failed to rally, then there would be no support for the shares going forward. Unfortunately, I didn’t “put my money where my mouth was”, because subsequent events proved my comments to be correct and the shares have dropped approximately 20% in the last month or so. I’m afraid the news doesn’t get any better, as, again looking at the chart, this share only has one way to go, and it will continue falling. There could be support at £6.00, and again at £5.00, but I won’t be around to see £5.00 tested if that were to happen and I have an opportunity to exit. To those of you who think charts are nonsense and it is all about the fundamentals, I say that the charts have called it absolutely right so far, in spite of broadly unchanged fundamentals. Indeed, looking at BTGs own forecasts, and almost universally those of the analysts, the outlook remains a positive as ever, so why the freefall? And where are the value buyers? The next few weeks will be a classic test of predicting share price by chart vs fundamentals. If the chart wins, we are heading lower, perhaps significantly. If the fundamentals are to be believed, then value investors should pile in before long. My own strategy is to continue holding, because my investment timeframe is 5 to 10 years, so perhaps one day this will be seen as just another pothole on the road to the FTSE 100. HOWEVER, if the shares fall to £5.80 and linger for more than a day or so, I’m out. Unfortunately I have seen too many extremely successful shares tank for no reason given the fundamentals, only to see that the fundamentals turned out to be hot air. The market (and the chart) usually (but not always!) knows best.
a1ord53: We Could Be Seeing A Buying Opportunity With Fast-Growers ARM Holdings plc And BTG plc By Motley Fool | Mon, 30th March 2015 - 09:16 Share this Markets go neither up nor down in straight lines. Every so often, rising share prices suffer a market 'correction' that could end up being nothing more than a brief interruption in upward progress. Not every reversal becomes a bear market If a firm's trading fundamentals don't change and the economic environment remains steady, there's every chance that lower share prices add up to nothing more than market jitters. Such share price reversals, as long as they prove to be temporary, could provide a better value buying opportunity as decent, well-performing companies sell for a lower price on the stock market. The 'trick' for us investors is to make sure a firm's underlying prospects haven't changed and that the valuation still makes sense. If those things seem in order, there's no reason to be shy about buying. Indeed, if we don't buy on market dips, when do we buy? Today, let's take a closer look at two companies with strong forecast earnings growth that have seen their share prices fall in the last few days, ARM Holdings (LSE:ARM) and BTG (LSE:BTG). Upbeat outlook On 11 February, chip designer ARM Holdings posted encouraging fourth-quarter results with strong revenue and growth in earnings. Back then, the chief executive said the firm saw strong licence revenue growth all through 2014, driven by market-leading semiconductor companies increasing their commitment to use ARM technology and a broadening range of new customers choosing ARM technology for the first time. The rate of growth for ARM's royalty revenue even increased during the fourth quarter. The top man reckons 2015 will be a year of exciting opportunities and challenges as ARM invests in new products and technologies, and continues to establish itself in competitive new markets. The firm continues to gain market share and, as chips based on ARMv8-A processors and Mali graphics IP start shipping in higher volumes, the outlook for royalty revenues in 2015 and beyond is encouraging, he says. Yet despite such a bright outlook, ARM Holdings' share price still sold off from recent highs around 1200p over the last few days to follow the stumbles of tech shares across the pond in the US. Can so much have changed for ARM's prospects since February, or is this little trip-up a good time for investors to top up? Exceeding expectations As I write, speciality pharmaceuticals company BTG (LSE:BTG) is also down, in excess of 15% from the 828p or so the share price achieved at the beginning of the year. The firm's overall performance during the year to date has been in line with the directors' expectations, they said, back in February with the interim results release. There's been an upgrade along the way with the company targeting full-year revenue in the range £345m-£360m, up from estimates of £330m to £345m. All seems well. BTG is a growing international specialist healthcare company that is developing and commercialising products targeting acute care, cancer and vascular diseases. The pharmaceutical sector has great longer-term fundamentals and clear growth drivers, and BTG occupies a sweet spot within the industry. The company enjoys diversified revenues from sales of self-marketed products and from royalties on partnered products. Forward earnings-growth projections remain robust. Perhaps it's the US economic growth figures spooking the market a little. A cooling in the fourth quarter saw general after-tax corporate profits record a drop as a strong dollar dented the earnings of multinational corporations. Who knows? There's always something to worry about as bull markets usually climb a wall of worry. Kevin Godbold owns shares in ARM Holdings and BTG. The Motley Fool UK has recommended ARM Holdings and BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
a1ord53: It looks like high flight of BTG share price is over .No support chart wise and no news flow.I also not sure what news we will get ? Hopefully good :) Anybody knows how Varethena and Eco Sphere progressing , also nothing heard on beads business and when we will have BTG year results -in April,May or in March ? Thanks a lot in advance for sharing thoughts and info :)
BTG share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180225 16:06:53